Cytocell Technologies Completes Management Buy-Out. Management Team Takes Control of Biotech Diagnostic Screening Company

Cambridge, England., March 1, 2005 - Cytocell Technologies Limited a leading provider of innovative DNA screening solutions for fast and accurate detection of human genetic diseases in Cytogenetics and Cancer, has undergone a management buy-out from Cytomyx Holdings Plc. The acquisition includes all intellectual property covering Cytocell’s unique technology and registered designs including the future product pipeline.

"We are extremely pleased to have completed the buy-out, and to report that the management team now holds controlling shares in the firm," said Dr Martin Lawrie -Managing Director. "This significant event signals a new era for Cytocell, and we are energized by what the future holds for our team," said Dr Brian Page - CEO.

The firm has shown consistent growth and increased revenues over the past 12 months. Dr Lawrie projects that Cytocell will show strong growth as new products come on stream later this year.

About Cytocell:

Cytocell's products are focused on the use of innovative DNA technologies in the areas of molecular cytogenetics and molecular genetics. DNA FISH (Fluorescence In Situ Hybridisation) probes form the main product ranges currently available from Cytocell.

Cytocell's products are manufactured in facilities based in Cambridge, UK, in accordance with the relevant ISO international quality standards and the FDA quality systems regulations.

Cytocell's future strategy is to build on its current product portfolio to provide more innovative screening solutions to customers worldwide with particular emphasis on Cancer genetics.

Cytocell Products:

Chromoprobe Multiprobe System offers a unique system for the simultaneous detection of banks of probes using standard fluorescence microscopy. It utilises a glass device, which allows the independent hybridisation of several probes on a single slide.

Aquarius® Liquid DNA probes directly labelled DNA FISH probes available in a liquid format. The kits are supplied complete with DAPI counterstain. The protocol is rapid and simple and follows co-denaturation of the FISH probe and target DNA simultaneously.

For More Information:

Dr Martin Lawrie

Managing Director

M_lawrie@cytocell.com

+44 1223 508191